Tarlatamab vs Standard of Care Chemotherapy in Patients With Pre-treated Advanced, Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Carcinomas (NECs)

Recruiting

Phase 3 — Large-scale testing across thousands of people, comparing the new treatment against current standard treatments.

Trial locations(40 sites)

France

Angers - CHU, Angers

Avignon - CH, Avignon

Besançon - CHU, Besançon

Boulogne - Ambroise Paré, Boulogne

Caen - CHU, Caen

Tours - CHU, Chambray-lès-Tours

Dijon - Centre Georges-François Leclerc, Dijon

Dijon - CHU Bocage, Dijon

Grenoble - CHU, Grenoble

Le Mans - CHG, Le Mans

Lille - Centre Oscar Lambret, Lille

Limoges - CHU, Limoges

Lyon - Centre Léon Bérard, Lyon

Lyon - Hôpital Edouard Herriot, Lyon

Lyon - Hôpital Privé Jean Mermoz, Lyon

Marseille - APHM, Marseille

Marseille - Institut Paoli-Calmettes, Marseille

Montpellier - CHU, Montpellier

Nice - Centre Antoine Lacassagne, Nice

Paris - Curie, Paris

Paris - Hôpital Cochin, Paris

Paris - Saint-Antoine, Paris

Paris - Tenon, Paris

Bordeaux - CHU, Pessac

Lyon - HCL, Pierre-Bénite

Poitiers - CHU, Poitiers

Reims - CHU, Reims

Rennes - CHU, Rennes

Rouen - CHU, Rouen

Nantes - Hôpital Laennec, Saint-Herblain

Nantes - Institut de Cancérologie de l'Ouest, Saint-Herblain

Strasbourg - Nouvel Hôpital Civil, Strasbourg

Toulon - CHI, Toulon

Toulouse - CHU, Toulouse

Tours - CHU, Tours

Vandoeuvre-lès-Nancy - Institut de Cancérologie de Lorraine, Vandœuvre-lès-Nancy

Villefranche sur Saône - CH, Villefranche-sur-Saône